Recent Updates
Recently added Catalysts
AMIX Positive Sentiment Score: 70/100

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the LSI USA ’25 Emerging Medtech Summit

Key Takeaway: Autonomix Medical, Inc. (NASDAQ: AMIX) has announced that its CEO, Brad Hauser, will present at the LSI USA ’25 Emerging Medtech Summit on March 18, 2025. The company is focused on innovative technologies for diagnosing and treating nervous system diseases, with a particular emphasis on an advanced catheter-based microchip sensing array. This platform technology, which has not yet received marketing clearance, is being developed to treat conditions like pancreatic cancer, aiming for improved sensitivity in neural signal detection. Autonomix will also engage in one-on-one meetings with qualified investors during the summit.

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation at a reputable medtech summit, increasing visibility.
  • Innovative technology aiming to revolutionize diagnosis and treatment.
  • Potential to address a wide range of neurological disorders.

CONCERNS & RISKS

  • Technology is still investigational and not yet cleared for marketing.
  • Dependence on successful trial outcomes for pancreatic cancer treatment.

Full Press Release Details

THE WOODLANDS, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the LSI USA ’25 Emerging Medtech Summit on Tuesday, March 18, 2025 at 7:35 AM PT.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
The in-person presentation will be accessible to those registered to attend the event. For more information, please visit the conference website.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact

Tags

SI USA ’25 Emerging Medtech

Frequently Asked Questions

When will Autonomix present at the LSI USA ’25 Summit?

Autonomix will present on March 18, 2025, at 7:35 AM PT.

What is the focus of Autonomix Medical, Inc.?

Autonomix focuses on advancing technologies for diagnosing and treating nervous system diseases.

What technology is Autonomix developing?

The company is developing a catheter-based microchip sensor with high sensitivity for neural signals.

What condition is Autonomix initially targeting?

They are initially targeting pain management related to pancreatic cancer.

Is Autonomix's technology approved for marketing?

No, the technology is investigational and not yet cleared for marketing in the U.S.

Last updated: Feb 26, 2025